26Apr 2022
Pretreatment lymphocyte count as independent prognostic factor in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy

Pretreatment lymphocyte count as independent prognostic factor in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy

To evaluate the association between pretreatment total lymphocyte counts (TLC) and survival outcomes in locally advanced cervical cancer (LACC) patients treated with definite concurrent chemoradiotherapy (CCRT). Fifty‐two patients had pretreatment TLC <1000 cells/mm3. The 5‐year DFS and OS rates were significantly higher in patients with pretreatment TLC >1000 cells/mm3 than their counterparts (67.7% vs 35.4% [P<0.0001] and 57.6% vs 25.7% [P<0.0001], respectively). In multivariate analysis, pretreatment TLC >1000 cells/mm3 was an independent predictor of DFS (HR, 0.39; 95% confidence interval [CI] 0.26‐0.59, P<0.001) and OS (HR, 0.59; 95% CI 0.42‐0.84, P=0.006). Therefore, Pretreatment TLC was associated with treatment response and survival outcome in patients with LACC treated with definite CCRT.

  • #gynaecology - ivf

Like

Save

Share